

Bader Alahmari

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5279775/publications.pdf>

Version: 2024-02-01

31
papers

329
citations

1307594

7
h-index

888059

17
g-index

31
all docs

31
docs citations

31
times ranked

541
citing authors

#	ARTICLE	IF	CITATIONS
1	HLA-identical related hematopoietic stem cell transplantation in severe sickle cell disease: age is not a barrier to successful outcome. <i>Bone Marrow Transplantation</i> , 2022, 57, 292-294.	2.4	1
2	Feasibility of early sirolimus cessation post non-myeloablative transplantation in adult patients with severe sickle cell disease. <i>Bone Marrow Transplantation</i> , 2022, 57, 319-322.	2.4	1
3	Post-CD19 Chimeric Antigen Receptor T-Cell Therapy Cytomegalovirus Retinitis. <i>Cureus</i> , 2022, 14, e23002.	0.5	1
4	Identification of Offspring Donors in Regions of High Consanguinity: New Prospects for Donor Procurement. <i>Transplantation Proceedings</i> , 2022, 54, 593-593.	0.6	0
5	Rates and predictors of infusion-related reactions in patients receiving standard versus prolonged infusion of rabbit anti-thymocyte globulin for hematopoietic stem cell transplantation, a retrospective analysis. <i>Bone Marrow Transplantation</i> , 2022, , .	2.4	0
6	Non-myeloablative human leukocyte antigen-matched related donor transplantation in sickle cell disease: outcomes from three independent centres. <i>British Journal of Haematology</i> , 2021, 192, 761-768.	2.5	41
7	Outcome of Middle East Respiratory Syndrome (MERS) in hematology and oncology patients: A case series in Saudi Arabia. <i>Journal of Infection and Public Health</i> , 2021, 14, 353-357.	4.1	0
8	Clinical course and outcomes of COVID-19 in hematopoietic cell transplant patients, a regional report from the Middle East. <i>Bone Marrow Transplantation</i> , 2021, 56, 2144-2151.	2.4	16
9	Management Approach to Acute Myeloid Leukemia Leveraging the Available Resources in View of the Latest Evidence: Consensus of the Saudi Society of Blood and Marrow Transplantation. <i>JCO Global Oncology</i> , 2021, 7, 1220-1232.	1.8	6
10	Infectious complications in adult sickle cell anemia patients undergoing hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 3078-3080.	2.4	1
11	Promising remissions in relapsed refractory classical Hodgkin lymphoma patients requiring multiple salvage regimens before transplantation in the brentuximab vedotin era. <i>Leukemia Research Reports</i> , 2021, 16, 100276.	0.4	0
12	Optimal pre-emptive cytomegalovirus therapy threshold in a patient population with high prevalence of seropositive status. <i>Current Research in Translational Medicine</i> , 2020, 68, 131-137.	1.8	3
13	Role of Allogeneic HCT as Postremission Therapy for Transplant-Eligible Adult Lymphoblastic Leukemia/Lymphoma After Frontline Hyper-CVAD. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 690-696.	0.4	1
14	Brentuximab vedotin containing salvage followed by consolidation post autologous hematopoietic stem cell transplantation in high risk relapsed refractory classical Hodgkin lymphoma. <i>Bone Marrow Transplantation</i> , 2020, 55, 2322-2325.	2.4	4
15	Selective targeting of $\alpha 4 \beta 1$ integrin attenuates murine graft versus host disease. <i>Leukemia</i> , 2020, 34, 3100-3104.	7.2	6
16	Impact of age and induction therapy on outcome of 180 adult patients with acute myeloid leukemia; retrospective analysis and literature review. <i>Leukemia Research Reports</i> , 2020, 14, 100206.	0.4	7
17	Clinicopathological Description from the Largest Series of Patients with the Novel Pro106Leu α MPL gene Mutation Associated with Hereditary Thrombocythemia. <i>Blood</i> , 2020, 136, 7-8.	1.4	0
18	Cluster of Differentiation 20 Expression and Rituximab Use Do Not Improve Outcome of Classical Hodgkin Lymphoma Patients. <i>Blood</i> , 2020, 136, 26-27.	1.4	0

#	ARTICLE	IF	CITATIONS
19	Home Care Program for Managing Oncology Patients during COVID-19 Pandemic. a Tertiary Referral Center Experience. <i>Blood</i> , 2020, 136, 21-21.	1.4	0
20	Favourable Outcome of Non Myeloablative Allogeneic HSCT in Adult Patients with Severe Sickle Cell Disease: A Single Center Experience of 110 Patients. <i>Blood</i> , 2020, 136, 1-2.	1.4	1
21	Therapeutic Potential of Checkpoint Inhibitors in Refractory Plasmablastic Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e559-e563.	0.4	13
22	HLA genotype and response to nivolumab therapy in relapsed refractory primary mediastinal B-cell lymphoma. <i>Current Research in Translational Medicine</i> , 2019, 67, 31-33.	1.8	2
23	Interim Functional Imaging Is an Independent Predictor of Progression-free Survival in Advanced Classical Hodgkin Lymphoma – A Real-world Analysis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e71-e79.	0.4	4
24	Chemoimmunotherapy with brentuximab vedotin combined with ifosfamide, gemcitabine, and vinorelbine is highly active in relapsed or refractory classical Hodgkin lymphoma. <i>Bone Marrow Transplantation</i> , 2019, 54, 1168-1172.	2.4	12
25	Baricitinib-induced blockade of interferon gamma receptor and interleukin-6 receptor for the prevention and treatment of graft-versus-host disease. <i>Leukemia</i> , 2018, 32, 2483-2494.	7.2	61
26	Selective targeting of histone modification fails to prevent graft versus host disease after hematopoietic cell transplantation. <i>PLoS ONE</i> , 2018, 13, e0207609.	2.5	6
27	Peripheral hematopoietic stem cell mobilization utilizing growth factors in donors with sickle cell trait is safe and effective. <i>Bone Marrow Transplantation</i> , 2018, 53, 1366-1368.	2.4	3
28	Graft vs host disease impacts overall survival post allogeneic hematopoietic stem cell transplantation for acute lymphoblastic leukemia/lymphoma. <i>World Journal of Transplantation</i> , 2018, 8, 252-261.	1.6	3
29	Pharmacologic Blockade of JAK1/JAK2 Reduces GvHD and Preserves the Graft-Versus-Leukemia Effect. <i>PLoS ONE</i> , 2014, 9, e109799.	2.5	123
30	Targeting VLA-4 to Reduce GvHD. <i>Blood</i> , 2014, 124, 3829-3829.	1.4	13
31	Pro106Leu MPL mutation is associated with thrombocytosis and a low risk of thrombosis, splenomegaly and marrow fibrosis. <i>Platelets</i> , 0, , 1-8.	2.3	0